ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1526

Employment and Quality of Life Among Patients with Rheumatoid Arhtritis in Four Latin-American Countries

Ricardo Xavier1,2, Fernando Chalem3, Javier Duhau4, Jorge Morales5,6, Cesar Ramos-Remus7, Jose Fernando Molina8, Eugenia Carnide9 and Annette Perez-Gilbe10, 1Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 2RUA ATILIO BILIBIO, 120 CASA 9, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, 3Fundación Instituto de Reumatología Fernando Chalem, Bogota, Colombia, 4Centro de Investigaciones en Enfermedades Reumáticas (CIER), Buenos Aires, Argentina, 5Imagenology X ray, Hospital de Especialidades Centro Medico La Raza IMSS, Mexico, Mexico, 6Rheumatology, Hospital Aranda de la Parra, Leon, Mexico, 7Unidad de Investigacion en Enf. Cronico-Degenerativas, Guadalajara, Mexico, 8Reumalab, Medellín, Colombia, 9Abbvie Inc, São Paulo, Brazil, 10Abbvie Inc, San Juan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Employment, quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Rheumatoid Arthritis impacts negatively on quality of life and work productivity. There are virtually no data on the employment status and burden of disease in RA patients from Latin-America (LA).  To assess the burden of RA on work productivity and health related quality of life in LA patients. 

Methods: Consecutive RA patients attending 20 rheumatology outpatient clinics distributed in Argentina, Brazil, Colombia and Mexico were included and completed the following standard questionnaires: Workplace Activity Limitations Scale (WALS), Work Productivity and Activity Impairment (WPAI), Work Limitations Questionnaire (WLQ), EuroQol (EQ-5D) and Short Form 36 Health Survey (SF-36). Sociodemographic data were also collected.

Results: The study included 309 patients, 90% female, mean age of 43 years (SD 9) and disease duration of 8 years (SD 8). At least 40% of patients reported some difficulty in all workplace activities (WALS), especially “crouching, bending, kneeling or working in awkward positions” (83%) and “lifting, carrying or moving objects” (80%). WPAI showed employment rate of 58%, and mean work time lost in a week of 4.3hs (SD 15.8). For WLQ, physical job demands were affected in 42% of patients followed by time demands in 34%. Mean self-evaluated health status using EQ-5D visual analogue scale (where 0=worst and 100=best health status) was 69 (SD 20), ranging from 63 (SD 22) in Brazil to 75 (SD 21) in Mexico. EQ-5D dimension mostly impaired was pain and discomfort with only 20.3% reporting have no problems in that dimension, while 72% reported have no problems with self-care. SF-36 physical and mental component scores for the total sample were 39 (SD 9.8) and 45(SD 11.4), respectively. Lower values were observed for the physical component in Brazil (34) and the mental component in Argentina and Colombia (44). The table below summarizes these results for each country analyzed. 

Conclusion: RA affects both work performance and quality of life in a substantial proportion of patients. Although similar trends were shown among countries, Brazilian patients reported to be more affected in most of evaluated aspects.


Disclosure: R. Xavier, AstraZeneca, 5,Hospira, 5,Janssen Pharmaceutica Product, L.P., 5,Pfizer Inc, 5,AbbVie, 8,AstraZeneca, 8,Janssen Pharmaceutica Product, L.P., 8,Pfizer Inc, 8,Roche Pharmaceuticals, 8; F. Chalem, Abbvie, 5; J. Duhau, Abbvie, 2; J. Morales, Abbvie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi and Servier, 5; C. Ramos-Remus, None; J. F. Molina, Abbvie, 2; E. Carnide, Abbvie, 3; A. Perez-Gilbe, Abbvie, 3.

To cite this abstract in AMA style:

Xavier R, Chalem F, Duhau J, Morales J, Ramos-Remus C, Molina JF, Carnide E, Perez-Gilbe A. Employment and Quality of Life Among Patients with Rheumatoid Arhtritis in Four Latin-American Countries [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/employment-and-quality-of-life-among-patients-with-rheumatoid-arhtritis-in-four-latin-american-countries/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/employment-and-quality-of-life-among-patients-with-rheumatoid-arhtritis-in-four-latin-american-countries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology